Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 126

Related Citations for PubMed (Select 12141889)

1.

Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.

Palmer CS, Nuijten MJ, Schmier JK, Subedi P, Snyder EH.

Pharmacoeconomics. 2002;20(9):617-28.

PMID:
12141889
2.

Treatment of advanced Parkinson's disease in the United States: a cost-utility model.

Groenendaal H, Tarrants ML, Armand C.

Clin Drug Investig. 2010;30(11):789-98. doi: 10.2165/11538520-000000000-00000.

PMID:
20818839
3.

Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.

Findley LJ, Lees A, Apajasalo M, Pitkänen A, Turunen H.

Curr Med Res Opin. 2005 Jul;21(7):1005-14.

PMID:
16004667
4.

Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis.

Nuijten MJ, van Iperen P, Palmer C, van Hilten BJ, Snyder E.

Value Health. 2001 Jul-Aug;4(4):316-28.

PMID:
11705299
5.

Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.

Hudry J, Rinne JO, Keränen T, Eckert L, Cochran JM.

Ann Pharmacother. 2006 Apr;40(4):651-7. Epub 2006 Mar 28.

PMID:
16569799
6.

Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.

Noyes K, Dick AW, Holloway RG; Parkinson Study Group.

Pharmacoeconomics. 2005;23(12):1257-70.

PMID:
16336019
7.

A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK.

Lowin J, Bergman A, Chaudhuri KR, Findley LJ, Roeder C, Schifflers M, Wood E, Morris S.

J Med Econ. 2011;14(5):584-93. doi: 10.3111/13696998.2011.598201. Epub 2011 Jul 6.

PMID:
21728911
8.

Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson's disease in Sweden: an exploratory study.

Kristiansen IS, Bingefors K, Nyholm D, Isacson D.

Appl Health Econ Health Policy. 2009;7(3):167-80. doi: 10.2165/11312780-000000000-00000.

PMID:
19799471
9.
11.
12.

Levodopa therapy with entacapone in daily clinical practice: results of a post-marketing surveillance study.

Kupsch A, Trottenberg T, Bremen D.

Curr Med Res Opin. 2004 Jan;20(1):115-20.

PMID:
14741081
13.
14.

Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.

Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, Hubble J; US01 Study Team.

Arch Neurol. 2004 Oct;61(10):1563-8.

PMID:
15477510
16.

Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.

Fung VS, Herawati L, Wan Y; Movement Disorder Society of Australia Clinical Research and Trials Group; QUEST-AP Study Group.

Mov Disord. 2009 Jan 15;24(1):25-31. doi: 10.1002/mds.21878.

PMID:
18846551
17.
18.
19.
20.

Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.

Reichmann H, Boas J, Macmahon D, Myllyla V, Hakala A, Reinikainen K; ComQol Study Group.

Acta Neurol Scand. 2005 Jan;111(1):21-8.

PMID:
15595934
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk